Eisai: Update On The Co-Promotion Of The Oral Antifungal Agent Nailin Capsules 100Mg In Japan
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan TOKYO, Mar 5, 2025 - (J ...
GlobalData on MSN15h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
AARP14h
Is It Too Soon to Diagnose Alzheimer’s in People With No Symptoms?
Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...
Science Media Centre9h
expert reaction to observational study of severity of menopause symptoms and cognition and behavioural impairment later in life
“This study adds to our understanding of how menopause may relate to brain health for women in later life. It suggests that women who experience more menopausal symptoms, report greater cognitive and ...
FierceBiotech18h
BMS pushes Fulcrum off its list of partners, scrapping MyoKardia heart muscle pact
Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...
DutchNews.NL11h
2024 Marks a Historic Year of Financial Performance for Havas
Record Net Revenue at 2,736 million euros, +1.5% Strong contribution to Net Revenue from acquisitions at +2.5% Adjusted EBIT ...
Aged Care Insite2h
TGA doubles down on rejection of Alzheimer’s drug
Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...